6 Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type
6.1 Introduction
Table 14 Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 15 Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (Units)
6.2 Autologous Stem Cell Therapies
6.2.1 Rising Incidence of Chronic Diseases to Drive Market
Table 16 Autologous Stem Cell Therapies Market, by Region, 2022-2029 (USD Million)
Table 17 North America: Autologous Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 18 Europe: Autologous Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 19 Asia-Pacific: Autologous Stem Cell Market, by Country, 2022-2029 (USD Million)
Table 20 Latin America: Autologous Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 21 Middle East: Autologous Stem Cell Market, by Region, 2022-2029 (USD Million)
Table 22 GCC Countries: Autologous Stem Cell Market, by Country, 2022-2029 (USD Million)
6.3 Autologous Non-Stem Cell Therapies
Table 23 Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 24 Autologous Non-Stem Cell Therapies Market, by Region, 2022-2029 (USD Million)
Table 25 North America: Autologous Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 26 Europe: Autologous Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 27 Asia-Pacific: Autologous Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
6.4 Car T-Cell Therapies
6.4.1 Growing Approval of Autologous Car T-Cell Therapies to Boost Growth
Table 28 Car T-Cell Therapies Market, by Region, 2022-2029 (USD Million)
Table 29 North America: Car T-Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 30 Europe: Car T-Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 31 Asia-Pacific: Car T-Cell Therapies Market, by Country, 2022-2029 (USD Million)
6.5 Tumor-Infiltrating Lymphocytes (Tils)
6.5.1 Emerging Potential of Til in Cancer Treatment to Boost Demand
Table 32 Tumor-Infiltrating Lymphocytes Market, by Region, 2022-2029 (USD Million)
Table 33 North America: Tumor-Infiltrating Lymphocytes Market, by Country, 2022-2029 (USD Million)
7 Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication
7.1 Introduction
Table 34 Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
7.2 Cancer Indication
7.2.1 Rising Incidence of Cancer and Growing Demand for Therapeutics to Drive Market
Table 35 Autologous Stem Cell & Non-Stem Cell Therapies Markey for Cancer Indications, by Region, 2022-2029 (USD Million)
Table 36 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Cancer Indications, by Country, 2022-2029 (USD Million)
Table 37 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market for Cancer Indications, by Country, 2022-2029 (USD Million)
Table 38 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market for Cancer Indications, by Country, 2022-2029 (USD Million)
7.3 Musculoskeletal Indication
7.3.1 Growing Incidence of Osteoarthritis to Drive Market
Table 39 Autologous Stem Cell & Non-Stem Cell Therapies Market for Musculoskeletal Indications, by Region, 2022-2029 (USD Million)
Table 40 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Musculoskeletal Indications, by Country, 2022-2029 (USD Million)
Table 41 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market for Musculoskeletal Indications, by Country, 2022-2029 (USD Million)
Table 42 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market for Musculoskeletal Indications, by Country, 2022-2029 (USD Million)
Table 43 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Musculoskeletal Indications, by Country, 2022-2029 (USD Million)
Table 44 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market for Musculoskeletal Indications, by Region, 2022-2029 (USD Million)
Table 45 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market for Musculoskeletal Indications, by Country, 2022-2029 (USD Million)
7.4 Dermatology Indication
7.4.1 Increasing Prevalence of Skin Disorders to Support Market Growth
Table 46 Autologous Stem Cell & Non-Stem Cell Therapies Market for Dermatological Indications, by Region, 2022-2029 (USD Million)
Table 47 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Dermatological Indications, by Country, 2022-2029 (USD Million)
Table 48 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market for Dermatological Indications, by Country, 2022-2029 (USD Million)
Table 49 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market for Dermatological Indications, by Country, 2022-2029 (USD Million)
Table 50 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Dermatological Indications, by Country, 2022-2029 (USD Million)
Table 51 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market for Dermatological Indications, by Region, 2022-2029 (USD Million)
Table 52 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market for Dermatological Indications, by Country, 2022-2029 (USD Million)
7.5 Other Indications
Table 53 Autologous Stem Cell & Non-Stem Cell Therapies Market for Other Indications, by Region, 2022-2029 (USD Million)
Table 54 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Other Indications, by Country, 2022-2029 (USD Million)
Table 55 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market for Other Indications, by Country, 2022-2029 (USD Million)
Table 56 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market for Other Indications, by Country, 2022-2029 (USD Million)
Table 57 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Other Indications, by Country, 2022-2029 (USD Million)
Table 58 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market for Other Indications, by Region, 2022-2029 (USD Million)
Table 59 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market for Other Indications, by Country, 2022-2029 (USD Million)
9 Autologous Stem-Cell & Non-Stem Cell Therapies Market, by End-user
9.1 Introduction
Table 72 Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
9.2 Hospitals and Clinics
9.2.1 Ability to Undertake Apheresis Procedures with Advanced Healthcare Infrastructure to Drive Market
Table 73 Autologous Stem Cell & Non-Stem Cell Therapies Market for Hospitals and Clinics, by Region, 2022-2029 (USD Million)
Table 74 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Hospitals and Clinics, by Country, 2022-2029 (USD Million)
Table 75 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market for Hospitals and Clinics, by Country, 2022-2029 (USD Million)
Table 76 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market for Hospitals and Clinics, by Country, 2022-2029 (USD Million)
Table 77 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Hospitals and Clinics, by Country, 2022-2029 (USD Million)
Table 78 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market for Hospitals and Clinics, by Region, 2022-2029 (USD Million)
Table 79 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market for Hospitals and Clinics, by Country, 2022-2029 (USD Million)
9.3 Long-Term Care Facilities
9.3.1 Rising Incidence of Chronic Diseases to Support Market Growth
Table 80 Autologous Stem Cell & Non-Stem Cell Therapies Market for Long-Term Care Facilities, by Region, 2022-2029 (USD Million)
Table 81 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Long-Term Care Facilities, by Country, 2022-2029 (USD Million)
Table 82 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market for Long-Term Care Facilities, by Country, 2022-2029 (USD Million)
Table 83 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market for Long-Term Care Facilities, by Country, 2022-2029 (USD Million)
Table 84 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Long-Term Care Facilities, by Country, 2022-2029 (USD Million)
Table 85 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market for Long-Term Care Facilities, by Region, 2022-2029 (USD Million)
Table 86 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market for Long-Term Care Facilities, by Country, 2022-2029 (USD Million)
9.4 Specialty Care Centers
9.4.1 Growing Preference for Personalized Medicine to Boost Demand
Table 87 Autologous Stem Cell & Non-Stem Cell Therapies Market for Specialty Care Centers, by Region, 2022-2029 (USD Million)
Table 88 North America: Autologous Stem Cell & Non-Stem Cell for Specialty Care Centers, by Country, 2022-2029 (USD Million)
Table 89 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market for Specialty Care Centers, by Country, 2022-2029 (USD Million)
Table 90 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market for Specialty Care Centers, by Country, 2022-2029 (USD Million)
Table 91 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market for Specialty Care Centers, by Country, 2022-2029 (USD Million)
Table 92 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market for Specialty Care Centers, by Region, 2022-2029 (USD Million)
Table 93 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market for Specialty Care Centers, by Country, 2022-2029 (USD Million)
10 Autologous Stem Cell and Non-Stem Stem Cell Therapies Market, by Region
10.1 Introduction
Table 94 Autologous Stem Cell & Non-Stem Cell Therapies Market, by Region, 2022-2029 (USD Million)
10.2 North America
10.2.1 North America: Recession Impact
Figure 31 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market Snapshot
Table 95 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 96 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 97 North America: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 98 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 99 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 100 North America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.2.2 US
10.2.2.1 Rising R&D Activities for Stem Cell Therapies to Drive Market
Table 101 US: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 102 US: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 103 US: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 104 US: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 105 US: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.2.3 Canada
10.2.3.1 Rising Government Initiatives for Regenerative Medicine Research to Drive Market
Table 106 Canada: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 107 Canada: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 108 Canada: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 109 Canada: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 110 Canada: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.3 Europe
10.3.1 Europe: Recession Impact
Table 111 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 112 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 113 Europe: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 114 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 115 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 116 Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.3.2 Germany
10.3.2.1 Rising Focus on Clinical Research to Drive Market
Table 117 Germany: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 118 Germany: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 119 Germany: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 120 Germany: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 121 Germany: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.3.3 UK
10.3.3.1 Rising Technological Advancements in Automation to Drive Market
Table 122 UK: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 123 UK: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 124 UK: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 125 UK: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 126 UK: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.3.4 France
10.3.4.1 Growing Focus on Cell & Gene Therapy Initiatives to Boost Demand
Table 127 France: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 128 France: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 129 France: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 130 France: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 131 France: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.3.5 Italy
10.3.5.1 Growth in Biotech Sector to Drive Market
Table 132 Italy: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 133 Italy: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 134 Italy: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 135 Italy: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 136 Italy: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.3.6 Spain
10.3.6.1 Rising Focus on Stem Cell Banking to Support Market Growth
Table 137 Spain: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 138 Spain: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 139 Spain: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 140 Spain: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 141 Spain: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.3.7 Rest of Europe
Table 142 Rest of Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 143 Rest of Europe: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 144 Rest of Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 145 Rest of Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 146 Rest of Europe: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.4 Asia-Pacific
10.4.1 Asia-Pacific: Recession Impact
Figure 32 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market Snapshot
Table 147 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 148 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 149 Asia-Pacific: Autologous Non-Stem Cell Therapies, by Type, 2022-2029 (USD Million)
Table 150 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 151 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 152 Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.4.2 Japan
10.4.2.1 Increasing Product Approvals to Drive Market
Table 153 Japan: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 154 Japan: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 155 Japan: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 156 Japan: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 157 Japan: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.4.3 China
10.4.3.1 Rising Number of Car T-Cell Clinical Trials to Support Market Growth
Table 158 China: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 159 China: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 160 China: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 161 China: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 162 China: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.4.4 India
10.4.4.1 Rising Incidence of Cancer and Growing Focus on Product Commercialization to Boost Demand
Table 163 India: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 164 India: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 165 India: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 166 India: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 167 India: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.4.5 South Korea
10.4.5.1 Rising Growth in Biopharmaceutical Industry to Drive Market
Table 168 South Korea: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 169 South Korea: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 170 South Korea: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 171 South Korea: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 172 South Korea: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.4.6 Rest of Asia-Pacific
Table 173 Rest of Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 174 Rest of Asia-Pacific: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 175 Rest of Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 176 Rest of Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 177 Rest of Asia-Pacific: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.5 Latin America
10.5.1 Latin America: Recession Impact
Table 178 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 179 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 180 Latin America: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 181 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 182 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 183 Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.5.2 Brazil
10.5.2.1 High Expenditure on Healthcare to Support Market Growth
Table 184 Brazil: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 185 Brazil: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 186 Brazil: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 187 Brazil: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 188 Brazil: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.5.3 Mexico
10.5.3.1 Low Operating Costs to Support Market Growth
Table 189 Mexico: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 190 Mexico: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 191 Mexico: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 192 Mexico: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 193 Mexico: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.5.4 Argentina
10.5.4.1 Funding for Stem Cell Research to Drive Market
Table 194 Argentina: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 195 Argentina: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 196 Argentina: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 197 Argentina: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 198 Argentina: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.5.5 Rest of Latin America
Table 199 Rest of Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 200 Rest of Latin America: Autologous Non-Stem Cell Therapies, by Type, 2022-2029 (USD Million)
Table 201 Rest of Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 202 Rest of Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 203 Rest of Latin America: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.6 Middle East
10.6.1 Middle East: Recession Impact
Table 204 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Region, 2022-2029 (USD Million)
Table 205 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 206 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 207 Middle East: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 208 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 209 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 210 Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.6.2 GCC Countries
Table 211 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Country, 2022-2029 (USD Million)
Table 212 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 213 GCC Countries: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 214 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 215 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 216 GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.6.2.1 Kingdom of Saudi Arabia (KSA)
10.6.2.1.1 Growing Demand for Novel Therapeutics to Boost Demand
Table 217 Kingdom of Saudi Arabia: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 218 Kingdom of Saudi Arabia: Autologous Stem Cell & Non-Stem Cell Therapies Market for Autologous Non-Stem Cell Therapies, by Type, 2022-2029 (USD Million)
Table 219 Kingdom of Saudi Arabia: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 220 Kingdom of Saudi Arabia: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 221 Kingdom of Saudi Arabia: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.6.2.2 United Arab Emirates (UAE)
10.6.2.2.1 Growing Focus on Automation of Platforms to Fuel Market
Table 222 United Arab Emirates: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 223 United Arab Emirates: Autologous Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 224 United Arab Emirates: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 225 United Arab Emirates: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 226 United Arab Emirates: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.6.2.3 Other GCC Countries
Table 227 Other GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 228 Other GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market for Autologous Non-Stem Cell Therapies, by Type, 2022-2029 (USD Million)
Table 229 Other GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 230 Other GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 231 Other GCC Countries: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.6.2.4 Rest of the Middle East
Table 232 Rest of Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 233 Rest of Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market for Autologous Non-Stem Cell Therapies, by Type, 2022-2029 (USD Million)
Table 234 Rest of Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 235 Rest of Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 236 Rest of Middle East: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.7 Africa
10.7.1 Improvements in Healthcare Infrastructure to Support Market Growth
Table 237 Africa: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type, 2022-2029 (USD Million)
Table 238 Africa: Autologous Stem Cell & Non-Stem Cell Therapies Market for Autologous Non-Stem Cell Therapies, by Type, 2022-2029 (USD Million)
Table 239 Africa: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Source, 2022-2029 (USD Million)
Table 240 Africa: Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication, 2022-2029 (USD Million)
Table 241 Africa: Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-user, 2022-2029 (USD Million)
10.7.2 Africa: Recession Impact
12 Company Profiles
12.1 Key Players
(Business Overview, Products Offered, Recent Developments, and Analyst's View (Key Strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 Bristol-Myers Squibb Company
Table 254 Bristol-Myers Squibb Company: Company Overview
Figure 42 Bristol-Myers Squibb Company: Company Snapshot (2023)
Table 255 Bristol-Myers Squibb Company: Products Offered
Table 256 Bristol-Myers Squibb Company: Product Approvals, January 2021-May 2024
Table 257 Bristol-Myers Squibb Company: Deals, January 2021- May 2024
12.1.2 Gilead Sciences, Inc.
Table 258 Gilead Sciences, Inc.: Company Overview
Figure 43 Gilead Sciences, Inc.: Company Snapshot (2023)
Table 259 Gilead Sciences, Inc.: Products Offered
Table 260 Gilead Sciences, Inc.: Product Approvals, January 2021-May 2024
Table 261 Gilead Sciences, Inc.: Deals, January 2021-May 2024
Table 262 Gilead Sciences, Inc.: Other Developments, January 2021-May 2024
12.1.3 Novartis AG
Table 263 Novartis AG: Company Overview
Figure 44 Novartis AG: Company Snapshot
Table 264 Novartis AG: Products Offered
Table 265 Novartis AG: Product Launches & Approvals, January 2021-May 2024
Table 266 Novartis AG: Expansions, January 2021-May 2024
Table 267 Novartis AG: Other Developments, January 2021-May 2024
12.1.4 Johnson & Johnson
Table 268 Johnson & Johnson: Company Overview
Figure 45 Johnson & Johnson: Company Snapshot (2023)
Table 269 Johnson & Johnson: Products Offered
Table 270 Johnson & Johnson: Product Approvals, January 2021-May 2024
Table 271 Johnson & Johnson: Deals, January 2021-May 2024
12.1.5 Vericel Corporation
Table 272 Vericel Corporation: Company Overview
Figure 46 Vericel Corporation: Company Snapshot (2023)
Table 273 Vericel Corporation: Products Offered
Table 274 Vericel Corporation: Expansions, January 2021-May 2024
12.1.6 Iovance Biotherapeutics, Inc.
Table 275 Iovance Biotherapeutics, Inc.: Company Overview
Figure 47 Iovance Biotherapeutics, Inc.: Company Snapshot (2023)
Table 276 Iovance Biotherapeutics, Inc.: Products Offered
Table 277 Iovance Biotherapeutics, Inc.: Product Approvals, January 2021-May 2024
Table 278 Iovance Biotherapeutics, Inc.: Expansions, January 2021-May 2024
12.1.7 Jw (Cayman) Therapeutics Co. Ltd
Table 279 Jw (Cayman) Therapeutics Co. Ltd.: Company Overview
Figure 48 Jw (Cayman) Therapeutics Co. Ltd.: Company Snapshot (2023)
Table 280 Jw (Cayman) Therapeutics Co. Ltd.: Products Offered
Table 281 Jw (Cayman) Therapeutics Co. Ltd.: Product Approvals, January 2021-May 2024
Table 282 Jw (Cayman) Therapeutics Co. Ltd.: Deals
12.1.8 Pharmicell Co. Ltd.
Table 283 Pharmicell Co. Ltd.: Company Overview
Table 284 Pharmicell Co. Ltd.: Products Offered
12.1.9 Holostem S.R.L.
Table 285 Holostem S.R.L.: Company Overview
Table 286 Holostem Srl: Products Offered
12.1.10 Healiva SA
Table 287 Healiva SA: Company Overview
Table 288 Healiva SA: Products Offered
Table 289 Healiva SA: Deals
12.1.11 Apac Biotech
Table 290 Apac Biotech: Company Overview
Table 291 Apac Biotech: Products Offered
12.1.12 Immunoadoptive Cell Therapy Private Limited (Immunoact)
Table 292 Immunoadoptive Cell Therapy Private Limited: Company Overview
Table 293 Immunoadoptive Cell Therapy Private Limited: Products Offered
Table 294 Immunoadoptive Cell Therapy Private Limited: Deals
Table 295 Immunoadoptive Cell Therapy Private Limited: Other Developments, January 2021-May 2024
12.1.13 Regrow Biosciences Pvt Ltd.
Table 296 Regrow Biosciences Pvt Ltd.: Company Overview
Table 297 Regrow Biosciences Pvt Ltd.: Products Offered
Table 298 Regrow Biosciences Pvt Ltd.: Product Approvals, January 2021-May 2024
12.1.14 Tego Science, Inc.
Table 299 Tego Science, Inc.: Company Overview
Table 300 Tego Science, Inc.: Products Offered
12.1.15 Carsgen Therapeutics Holdings Limited
Table 301 Carsgen Therapeutics Holdings Limited: Company Overview
Table 302 Carsgen Therapeutics Holdings Limited: Products Offered
Table 303 Carsgen Therapeutics Holdings Limited: Product Approvals, January 2021-May 2024
Table 304 Carsgen Therapeutics Holdings Limited: Expansions
Table 305 Carsgen Therapeutics Holdings Limited: Deals
12.1.16 Iaso Biotherapeutics
Table 306 Iaso Biotherapeutics: Company Overview
Table 307 Iaso Biotherapeutics: Products Offered
Table 308 Iaso Biotherapeutics: Product Approvals
Table 309 Iaso Biotherapeutics: Deals
12.1.17 Anterogen.Co.,Ltd.
Table 310 Anterogen.Co.,Ltd.: Company Overview
Table 311 Anterogen.Co.,Ltd.: Products Offered
12.1.18 Green Cross Holdings Co. Ltd. (Gc Cell)
Table 312 Green Cross Holdings Co. Ltd. (Gc Cell): Company Overview
Figure 49 Green Cross Holdings Co. Ltd. (Gc Cell): Company Overview (2023)
Table 313 Green Cross Holdings Co. Ltd. (Gc Cell): Products Offered
Table 314 Green Cross Holdings Co. Ltd. (Gc Cell): Deals
12.1.19 Sanpower Group Co. Ltd. (Dendreon Pharmaceuticals LLC.)
Table 315 Sanpower Group Co. Ltd.: Company Overview
Table 316 Sanpower Group Co. Ltd. (Dendreon): Products Offered
12.2 Other Players
12.2.1 Prokidney Corp.
Table 317 Prokidney Corp.: Company Overview
12.2.2 Biocardia, Inc.
Table 318 Biocardia, Inc.: Company Overview
12.2.3 Neuroplast B.V.
Table 319 Neuroplast B.V.: Company Overview
12.2.4 Adaptimmune Therapeutics PLC
Table 320 Adaptimmune Therapeutics PLC.: Company Overview
12.2.5 Agonox, Inc.
Table 321 Agonix, Inc.: Company Overview
12.2.6 Kyverna Therapeutics, Inc.
Table 322 Kyverna Therapeutics, Inc.: Company Overview
12.2.7 Obsidian Therapeutics, Inc.
Table 323 Obsidian Therapeutics, Inc.: Company Overview
12.2.8 Avotres Inc.
Table 324 Avotres, Inc.: Company Overview
12.2.9 Corestemchemon Inc.
Table 325 Corestemchemon Inc.: Company Overview
12.2.10 Juventas Cell Therapy Ltd.
Table 326 Juventas Cell Therapy Ltd.: Company Overview
*Details on Business Overview, Products Offered, Recent Developments, and Analyst's View (Key Strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) Might Not be Captured in Case of Unlisted Companies.